Interval cancers in nasopharyngeal carcinoma screening: Comparing two screening intervals after a negative initial screening result

Journal of Medical Screening

Volumn 19, Issue 4, 2012, Pages 195-200

  Chen, Feng ^a   Huang, Qi Hong ^b   Fang, Fang ^c   Liu, Zhi Wei ^a   Liu, Ke ^a,d   Xie, Shang Hang ^a   Liu, Qing ^a   Hong, Ming Huang ^a   Liao, Zhen Er ^a   Ye, Wei Min ^c   Zeng, Yi Xin ^a   Cao, Su Mei ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Sihui Cancer Institute   (China)

^c KAROLINSKA INSTITUTE   (Sweden)

^d HUNAN CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ARTICLE; BLOOD; CHINA; COMPARATIVE STUDY; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; IMMUNOLOGY; INCIDENCE; MALE; MIDDLE AGED; NASOPHARYNX CARCINOMA; NASOPHARYNX TUMOR; NEOPLASM; STATISTICS; TIME; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CHINA; EARLY DETECTION OF CANCER; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN A; INCIDENCE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASMS; TIME FACTORS;

EID: 84878322134     PISSN: 09691413     EISSN: 14755793     Source Type: Journal    
DOI: 10.1258/jms.2012.012068     Document Type: Article

References (32)

1. Jia WH, Huang QH, Liao J, et al. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983- 2002) in Sihui and Cangwu counties in southern China. BMC Cancer 2006;6:178
2. Cao SM, Liu Z, Jia WH, et al. Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: A prospective screening study with a 20-year follow-up. PloS ONE 2011;6:e19100
3. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:1765-1777
4. NG MH, Chan KH, NG SP, Zong YS. Epstein-Barr virus serology in early detection and screening of nasopharyngeal carcinoma. Chin J Cancer 2006;25:250-6
5. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 2011;30:114-119
6. Dong ZW. The technical guidelines on cancer screening and early diagnosis and Treatment in China. Beijin: People's medical publishing house, 2009
7. Ji MF, Yu YL, Cheng WM. Detection of Stage I nasopharyngeal carcinoma by serologic screening and clinical examination. Chin J Cancer 2011;30:120-123
8. Zeng Y, Zhang LG, Li HY, et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 1982;29:139-141
9. Zeng Y, Zhang LG, Wu YC, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibodypositive persons in Wuzhou City, China. Int J Cancer 1985;36:545-547
10. Zong YS, Sham JS, Ng MH, et al. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 1992;69:3-7
11. Ji MF, Wang DK, LYu Y, et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer 2007;96:623-630
12. Ito K, Yamamoto T, Ohi M, et al. Possibility of rescreening intervals of more than one year in men with PSA levels of 4.0ng/ml or less. Prostate 2003;57:8-13
13. Sennfalt K, Sandblom G, Carlsson P, Varenhorst E. Cost and effects of prostate cancer screening in Sweden-a 15-year follow-up of a randomized trial. Scand J Urol Nephrol 2004;38:291-298
14. Roobol MJ, Grenabo A, Schroder FH, Hugosson SJ. Interval cancers in prostate cancer screening: comparing 2- and 4- year screening intervals in the European randomized study of screening for prostate cancer, Gothenburg and Rotterdam. J Natl Cancer Inst 2007;99:1296-1303
15. Cheng SH, Yen KL, Jian JJ, et al. Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. Int J Radiat Oncol Biol Phys 2001;50:717-726
16. Lin JC, Liang WM, Jan JS, Jiang RS, Lin AC. Another way to estimate outcome of advanced nasopharyngeal carcinoma - is concurrent chemoradiotherapy adequate? Int J Radiat Oncol Biol Phys 2004;60:156-164
17. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little Brown & Co., 1997
18. Singh H, Turner D, Lin X, Targownik LE, Bernstein CN. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-Year interval between colonoscopies JAMA 2006;295:2366-73
19. Bailar JI, Ederer F. Significance factors for the ratio of a poisson Vstisble to its expectation. Biometrics 1964;20:639-643
20. Chen HH, Prevost TC, Duffy SW. Evaluation of screening for nasopharyngeal carcinoma: trial design using Markov chain models. Br J Cancer 1999;79:1894-1900
21. Choi CW, Lee MCH, Ng WT, et al. An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models. Fam Cancer 2011;10:133-139
22. Bordas P, Jonsson H, Nystrom L, Lenner P. Interval cancer incidence and episode sensitivity in the Norrbotten mammography screening programme, Sweden. J Med Screen 2009;16:39-45
23. Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001;345:1877-1882
24. Lin JC, Jan JS, Hsu CY, Jiang RS, Wang WY. Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates. Br J Cancer 2003;88:187-194
25. Lo S, Ho WK, Wei WI. Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong. Arch Otolaryngol Head Neck Surg 2004;130:770-2
26. Yi Z, Yuxi L, Chunrenl L, et al. Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. Intervirology 1980;13:162-168
27. Zeng Y, Zhong JM, Li LY, et al. Follow-up studies on Epstein-Barr virus IgA/ VCA antibody-positive persons in Zangwu County, China. Intervirology 1983;20:190-4
28. Lo Y, Chan A, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000;60:6878-6881
29. Lo Y, Chan L, Chan A, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res 1999;59:5452-5455
30. Lo Y, Chan L, Lo K, et al. Quantitative analysis of cell-free Epstein Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1189-1191
31. Chan K, Zhang J, Chan A, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003;63:2028-2032
32. Yang X, Goldstein A, Chen C, et al. Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan. Int J Cancer 2006;118:780-784